Cannaray Funding: How Much Did They Raise & Key Investors

How Much Did Cannaray Raise?
Funding & Key Investors

Cannaray, a prominent UK-based medical cannabis and CBD enterprise, has secured $9.6M in total financing, with its most recent capital infusion amounting to $9.6M. This major strategic investment underscores the company's significant progress and market positioning within the burgeoning cannabis sector.

The company's funding history, beginning with its Series A round on September 9, 2019, indicates a trajectory of sustained growth and investor confidence.

What is Cannaray?

Cannaray

Manufacturing

Pharmaceuticals

Business Services

Cannaray distinguishes itself as the sole UK entity operating in the medical cannabis and CBD space that boasts a Scientific Advisory Board. This board comprises key opinion leaders across five critical areas of medical cannabis application in the UK: Multiple Sclerosis, Chemo-Induced Nausea and Vomiting, Epilepsy, Chronic Pain, and Tourette's syndrome. The establishment of this expert panel highlights Cannaray's commitment to scientific rigor and evidence-based approaches in its operations.

How much funding has Cannaray raised?

Cannaray has raised a total of $9.6M across 1 funding round:

2019

Series A

$9.6M

Series A (2019): $9.6M, investors not publicly disclosed

What's next for Cannaray?

With a substantial enterprise-level funding context, Cannaray is poised for significant scaling and expansion. The recent strategic investment suggests a focus on solidifying its market leadership, potentially through further research and development, expanding its product portfolio, or enhancing its distribution networks. The company's strong scientific foundation, coupled with this latest backing, positions it for continued advancement in the regulated medical cannabis market.

See full Cannaray company page

See More Financial Insights